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Human  immunodeﬁciency  virus  (HIV)  is the  cause  of  one  of the  most  lethal  pandemics  in  human  history,
although  in  recent  years  access  to  highly  effective  anti-retroviral  therapy  has provided  new  hope  world-
wide.  Transmission  of HIV by  sexual  contact,  childbirth  and  injection  drug  use  has  been  reduced,  but  2
million  are  newly  infected  each  year,  and  much  of  the  transmission  is from  people  who  do  not  know  their
status.  In addition  to known  methods,  a preventive  vaccine  is  needed  to end  the pandemic.  The  extraordi-
nary  mutability  and  genetic  diversity  of  HIV  is an  enormous  challenge,  but  vaccines  are  being  designed  for
broad coverage.  Computer-aided  design  of  mosaic  immunogens,  incorporating  many  epitopes  from  the
entire genome  or from  conserved  regions  aim  to  induce  CD8+  T cells  to  kill  virus-infected  cells  or  inhibit
virus  replication,  while  trimeric  envelope  proteins  or synthetic  mimics  aim to induce  broadly  reactive
neutralizing  antibodies  similar  to those  cloned  from  some  infected  patients.  Induction  of more  potent
and  durable  responses  may  require  new  adjuvants  or replicating  chimeric  vectors  chimeras  that  bear
HIV genes.  Passive  or  genetic  delivery  of  broadly  neutralizing  antibodies  may  provide  broad  protection
and/or  lead  to insights  for  vaccine  designers.  Proof-of-concept  trials  in  non-human  primates  and  in  one
human efﬁcacy  trial have  provided  scientiﬁc  clues  for  a vaccine  that  could  provide  broad  and  durable
protection  against  HIV.  The  use of  vaccines  to destroy  HIV reservoirs  as  part  of therapy  or  cure is  now
also  being  explored.
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Since the initial recognition of an acquired immunodeﬁciency
yndrome (AIDS) in 1981 through the presentation of rare Pneu-
ocystis carinii pneumonia among homosexual men  in the USA,
uman immunodeﬁciency virus type 1 (HIV-1) has given rise to a
andemic of nearly unprecedented proportion, causing extensive
lobal morbidity and mortality [1,2]. Because the virus targets an
mmune system that has evolved to ﬁght such pathogens, AIDS is
haracterized by a progressive loss of HIV’s preferred target, CD4+
 cells, and chronic immune activation resulting in an immunode-
ciency syndrome that allows numerous opportunistic infections
nd cancers, typically leading to serious morbidity and mortality in
he absence of treatment. Since 1981, over 70 million people have
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been infected with HIV resulting in 36 million deaths. UNAIDS
estimates that, in 2014 alone, nearly 37 million persons were
living with HIV, 2 million were newly infected, and 1.2 million died
from their infection, most of whom were in sub-Saharan Africa
[3]. HIV, although not as easily transmitted as some viruses, can
be transmitted with varying efﬁciency by multiple modalities: via
injection of blood or blood-derived products; from mother-to-child
during pregnancy, at delivery or through breast-feeding; and most
commonly through sexual intercourse [4]. Fortunately, signiﬁcant
research since the beginning of the epidemic has resulted in the
development of more than 40 anti-retroviral drugs that in various
combinations can help control the infection [5]. However, despite
major gains in the numbers of HIV infected individuals accessing
anti-retroviral therapy (ART) in recent years, in 2014 there were
still 59% of HIV-positive adults and 68% of children without access
to these life-saving medications and importantly, for every person
enrolled in treatment, a new infection occurred [6]. This is particu-
larly tragic because effective ART treatment almost eliminates the
chance of onward transmission of HIV [7]. Ultimately, even with
these signiﬁcant advances in ART and additional prevention efforts,
the development of a safe and effective HIV vaccine remains a
global public health priority that is the best hope for preventing,
ss article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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ontrolling and ending the AIDS pandemic. Even if other treatment
nd prevention tools are extensively scaled up, modeling analysis
hows that a 70-percent-efﬁcacious AIDS vaccine with strong
ptake could reduce new annual HIV infections in lower and
iddle income countries by 44% in 10 years and by 65% in 25
ears, ultimately averting tens of millions of infections and saving
illions of lives [8].
. Biological feasibility for prophylactic vaccine
evelopment
Unlike many infectious diseases, HIV infection does not resolve
nd give rise to protective immunity against subsequent expo-
ure. While some individuals remain uninfected despite multiple
xposures to HIV-1, immune-mediated correlates of protection
ave not been conclusively identiﬁed. Adaptive immune responses
gainst HIV are often directed toward the envelope (Env) protein
n the surface of the virus and the capsid protein (Gag) that
urrounds and protects the HIV RNA. In people who control virus
eplication and remain well for many years, Gag-speciﬁc CD8+ T
ells can inhibit HIV-1 replication in ex vivo-infected cells, a phe-
otype not observed in those who become ill more quickly [9]. The
ontribution of cellular immunity to controlling infection has also
een observed in simian immunodeﬁciency virus (SIV) challenge
tudies of rhesus macaques, although the correlates of protection
re not well understood. Pre-clinical studies have shown that
ecombinant cytomegalovirus (CMV) vectored SIV vaccines induce
D8+ effector memory cells—some conventionally restricted by
HC class I and some unconventional cells—that control SIV to
ndetectable levels in approximately 50% of immunized macaques
10]. These studies are providing clues toward understanding
ow best to elicit cellular immune responses that will control and
ossibly abort HIV infection.
Despite the importance of eliciting a robust cellular immune
esponse, most effective vaccines prevent infection by stimulat-
ng the development of neutralizing antibodies. About 5% of HIV
nfected individuals develop potent neutralizing antibodies against
nv that effectively neutralize a broad range of HIV-1 isolates
n vitro [11]. A number of broadly neutralizing human monoclonal
ntibodies (bNAbs) have been isolated and characterized in detail.
n vitro experiments have shown that combinations of such bNAbs
an prevent infection of human CD4+ T cells by virtually all HIV iso-
ates. In animal models, passive transfer of several different bNAbs
an prevent infection at antibody concentrations that should be
chievable by vaccination [12]. The activity and speciﬁcity of bNAbs
s currently guiding the design of immunogens to elicit broad virus
eutralization.
. Biological feasibility for therapeutic vaccine
evelopment
Therapeutic vaccines for HIV have been evaluated in the past
ith very limited and inconsistent success, when the model was
accination during untreated HIV infection [13]. Recently, an alter-
ative approach has been tested, which is to vaccinate patients
n highly effective ART, in the hope of preventing virus escape
nce treatment is stopped or effecting a cure by removing virus
eservoirs [14,15]. This approach will be hindered by the enor-
ous variation of HIV within each infected person, but might
old promise if vaccines that induce sufﬁciently broad, potent and
urable immune responses were employed.
. General approaches to vaccine development for this
isease for low and middle income country markets
Some two hundred HIV vaccine candidates/regimens have been
linically tested since 1986, yet efﬁcacy trials were completed for (2016) 2921–2925
only four vaccines [16], only one of which demonstrated modest
efﬁcacy in preventing HIV acquisition [17]. An Env subunit vaccine
(gp120, VaxGen) formulated in an alum adjuvant failed to elicit
antibodies that could neutralize most tested isolates or to pre-
vent or control HIV infection. An adenovirus type 5 vector with
a gag-pol-nef insert (Merck) not only failed to control HIV infection
but transiently potentiated HIV acquisition for reasons that remain
unclear. One possibility is that repeated vaccination with the Ad5
vector stimulated a generalized immune activation that then pro-
vided activated CD4+ target cells for HIV. More recently, a DNA
prime boosted with an Ad5 vector delivering gag-pol-nef and three
env genes (NIAID Vaccine Research Center) had no effect on HIV
infection or viral load in those who  became infected [18]. The most
promising product, a prime-boost regimen of a Canarypox vector
delivering gag-pol-env with a gp120 protein boost (ALVAC – Sanoﬁ;
gp120-Vaxgen), designed to elicit both cellular and humoral immu-
nity, demonstrated for the ﬁrst time that a vaccine could prevent
HIV acquisition with 31.2% overall efﬁcacy (RV144).
Once a safe and effective HIV vaccine is developed and licensed,
decisions will have to be made regarding which populations to tar-
get for vaccination. There is general consensus that priority should
be given to high risk groups exposed to HIV through sexual contact
or injection drug use. Vaccination of infants has also been pro-
posed and tested in previous early phase clinical studies, however
ancillary treatment with drugs or passive antibodies would likely
be needed to prevent infection initially, until the child’s immune
system responds to the vaccination [19,20].
4. Technical and regulatory assessment
HIV vaccine candidates are advanced on the basis of safety and
immunogenicity data from animal models and from Phase I clini-
cal trials. The primary HIV animal challenge models include Rhesus
macaques challenged with either SIV or a chimeric construct of
SIV and HIV Env (SHIV). The SIV or SHIV models are most often
chosen based on the availability of appropriate reagents (HIV vac-
cine candidates made in an SIV version or a SHIV constructed to
match the Env in the HIV vaccine candidate). The most common
SIV strain used, mac239, is very difﬁcult to neutralize and CD8+ T
cells provide limited protection against this virus. SHIV constructs,
however, are generally less virulent and are more easily neutralized
by antibodies to HIV Env.
More than 250 HIV vaccine Phase I and II clinical trials have
been conducted in more than 30 countries [16]. For an updated
list of the status of candidates in current developement, please see
Table 1. Although a clear correlate of protection remains elusive,
through pre-clinical and clinical evaluation, it is presumed that
the best vaccine candidates should elicit neutralizing antibodies,
non-neutralizing antibodies that mediate viral clearance through
other mechanisms (such as antibody-dependent cell-mediated
cytotoxicity-ADCC or virus inhibition, ADCVI), and T cells (primar-
ily CD8+) that suppress virus growth or kill virus-infected cells.
For example, efﬁcacy in the RV144 trial was associated with non-
neutralizing IgG antibodies to the V1V2 region of Env [21]. To
best predict correlates of vaccine efﬁcacy in the absence of addi-
tional successful Phase III trials, we  must turn to examples of virus
control in HIV infected humans and protection from infection or
disease in SIV or SHIV models. In humans, CD8+ T cells, partic-
ularly those directed at conserved regions of Gag, are correlated
with control of virus replication [9,22]. The general consensus is
that vaccine candidates should induce classical CD8+ T effector or
effector memory cells (restricted by Class I MHC). Interestingly,
however, some of the macaques that were protected from SIV chal-
lenge after vaccination with CMV  vectors expressing multiple SIV
antigens contained unconventional T effector cells [23]. Whether
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Table  1
Development status of current vaccine candidates.
Candidate name/trial identiﬁer Class/antigen Phase I Phase IIa
Ad26.EnvA-01/Ad26.ENVA.01 Adeno/Ad26 Env A X
VRC-HIVADV038-00-VP; VRC-HIVADV027-00-VP/VRC 012 (07-I-0167) Adeno/Ad35 Env A; Ad5 Env A X
VRC-HIVADV027-00-VP; VRC-HIVADV052-00-VP;
VRC-HIVADV038-00-VP/HVTN 083
Adeno/Ad35 Env A; Ad5 Env A; Ad5 Env B X
Ad26.EnvA-01/Ad26.ENVA.01 Mucosal/IPCAVD003 Adeno/Ad26 Env A X
VRC-HIVADV014-00-VP/VRC  015 (08-I-0171) Adeno/Ad5 Gag-Pol Env A/B/C X
Ad5HVR48.ENVA.01/Ad5HVR48.ENVA.01 Adeno/Ad5/Ad48 Env A X
VRC-HIVADV014-00-VP; VRC-HIVADV038-00-VP; VRC-HIVADV052-00-VP;
VRC-HIVADV054-00-VP; VRC-HIVADV053-00-VP/HVTN 085
Adeno/Ad5 Gag-Pol Env A/B/C; Ad5 Env A; Ad5 Env B; Ad5
Gag-Pol B; Ad5 Env C
X
rAd35 Env A; rAd5 Env A; rAd5 Env B/HVTN 083 Adeno/Env A, Env B X
VRC-HIVADV014-00-VP; VRC-HIVADV054-00-VP/HVTN 084 Adeno/Ad5 Gag-Pol Env A/B/C, Ad5 Gag-Pol B X X
MVA gag/pol/env mosaic inserts/IPCAVD006 Adeno and Pox/gag/pol/env mosaic X
ChAdV63.HIVconsv; MVA.HIVconsv; plus HCV vaccine/PEACHI-04 Adeno and Pox/ChimpAd63 consensus; MVA  consensus X
PENNVAX-GP/HVTN 098 DNA/Gag, Pol, Env B
VRC-HIVDNA016-00-VP; VRC-HIVADV014-00-VP/HVTN 076 DNA and Adeno/DNA Gag, Pol, Nef B, env A,B,C; Ad5 Gag-Pol
Env A/B/C
X
VRC-HIVDNA044-00-VP; VRC-HIVADV027-00-VP;
VRC-HIVADV038-00-VP/HVTN 077
DNA and Adeno/DNA Env A; Ad35 Env A; Ad5 Env A X
VRC-HIVDNA016-00-VP; VRC-HIVADV014-00-VP/HVTN 082 DNA and Adeno/DNA Gag, Pol, Nef B, Env A,B,C; Ad5 Gag-Pol
Env A/B/C
X
DNA Nat-B env; DNA CON-S env; DNA Mosaic env; MVA-CMDR/HVTN 106 DNA and Pox/DNA Nat-B env; DNA CON-S env; DNA Mosaic
env; MVA  Gag-Pol, Env E
X
DNA-HIV-PT123; NYVAC-HIV-PT1; NYVAC-HIV-PT4/HVTN 092 -01 DNA and Pox/DNA Gag, Env, Pol-Nef C; NYVAC Gag, Env,
Pol-Nef C
X
MVA-CMDR; Pennvax-G/RV262 DNA and Pox/MVA Gag-Pol, Env E; DNA Env A,C,D, Gag
consensus
X
GEO-D03; MVA/HIV62/HVTN 094 DNA and Pox/DNA Gag, PR, RT, Env, Tat, Rev, Vpu B; MVA  Gag,
Pol Env B
X
HIVIS-DNA; MVA-CMDR/TaMoVac II DNA and Pox/DNA env, rev, gag, and RT A/B/C, MVA  Gag-Pol,
Env E
X
HIV-MAG; VSV-Indiana HIV gag vaccine/HVTN 087 DNA and Replicating Vector/D¨NA Gag, Pol, Nef Tat, Vif, Env B;
Replicating VSV Gag
X
Tiantan vaccinia; Chinese DNA/Tiantan vaccinia HIV Vaccine and DNA DNA and Replicating Vector/Replicating tiantan Gag, Pol, Env
B’/C; DNA Gag, Pol, Env B’/C
X
pSG2.HIVconsv DNA, MVA.HIVconsv and Ad35-GRIN/IAVI
N004/HIVCORE004/IPCAVD009
DNA, Adeno and Pox/MVA consensus; DNA consensus; Ad35
Gag, RT, Integ, Nef A
X X
MVA.HIVconsv; pSG2.HIVconsv; ChAdV63.HIVconsv/HIV-CORE002 DNA, Adeno and Pox/MVA consensus; DNA consensus;
ChimpAd63 consensus
X
LIPO-5; MVA-B; GTU-MultiHIV/VRI01 DNA, Pox, Protein/Protein Gag, Nef, Pol B; MVA  Nef; Gag; Pol B;
DNA Rev, Nef, Tat, Pol, Env B
X X
SAAVI DNA-C2; SAAVI MVA-C; Oligomeric gp140/MF59/HVTN 086, SAAVI 103 DNA, Pox, Protein/DNA Gag, RT, Tat, Nef, Env C; MVA  Gag, RT,
Tat, Nef, Env C; Protein Env
X
DNA - CN54ENV and ZM96GPN; CN54gp140; MVA-C/UKHVCSpoke003 DNA, Pox, Protein/DNA Gag, Pol, Nef C, MVA  Gag, Pol, Nef C,
Protein Enc C
X
MVA-CMDR/RV 365 Pox/MVA Gag-Pol, Env E X
ALVAC-HIV vCP1521; AIDSVAX B/E/RV 306 Pox and Protein/Canarypox Env B,E; Protein Env B,E X
ALVAC-HIV vCP1521; AIDSVAX B/E/HVTN 097 Pox and Protein/Canarypox Env B,E; Protein Env B,E X
ALVAX pox prime with protein boost and MF59/HVTN 100 Pox and Protein/Canarypox Env B,E; Protein Env B,E X X
ALVAC-HIV vCP1521; AIDSVAX B/E/RV 305 Pox and Protein/Canarypox Env B,E; Protein Env B,E X
Trimeric gp140/IPCAVD008 Protein/gp140 X
CN54gp140/CN54gp140 mixed with GLA-AF Protein/Env C X
AIDSVAX®B/E;  DNA-HIV-PT123/HVTN 105 Protein and DNA/DNA: clade C ZM96 Gag and gp140, CN54
Pol-Nef. Protein: clade B (MN) HIVgp120 glycoprotein clade E
(A244) HIV gp120 glycoprotein
X
AIDSVAX®B/E; DNA-HIV-PT123/IDEA EV06 Protein and DNA/DNA: clade C ZM96 Gag and gp140, CN54
Pol-Nef. Protein: clade B (MN) HIVgp120 glycoprotein clade E
(A244) HIV gp120 glycoprotein
X
AIDSVAX B/E/RV 328 Protein/Env B,E X
Ad26/R001 Replicating Vector/Ad26 Env X
Ad4-EnvC150; Ad4-mgag/PXVX-HIV-100-001/HVTN 110 Replicating Vector/Replicating Ad4 Env C; Replicating Ad4 Gag X
VSV-Indiana HIV gag vaccine/HVTN 090 Replicating Vector/Replicating VSV Gag X
eV-G;  Ad35-GRIN/IAVI S001 Replicating Vector and Adeno/Sendai Gag A; Ad35 Gag, RT,
Integ, Nef A
X
Vecto
Imm
t
H
n
m
r
fAAV1-PG9/IAVI A003 
VRC-01/IMPAACT P1112 
hese unconventional responses will also be effective in controlling
IV in humans remains to be seen.
Phase III HIV vaccine efﬁcacy trials have enrolled a heteroge-eous array of populations, including men  who  have sex with
en, injection drug users, heterosexual men  and women at high
isk for HIV infection, and members of the general population
rom across global regions in the Americas, South Africa andred Immunoprophylaxis/AAV1 vectored PG9 X
unoprophylaxis/VRC-01 antibody X
Thailand. As other proven non-vaccine prevention methods, such
as treatment-as-prevention, voluntary medical male circumcision
and pre-exposure prophylaxis with antiretroviral drugs become
more widely available, it will be more difﬁcult to ﬁnd appro-
priate at-risk individuals for vaccine trials, and questions may
be raised about the standard of preventive interventions that is
required in these trials. Consultation with involved communities
2 ine 34
w
t
a
5
l
&
(
n
i
a
t
a
c
S
c
r
g
a
h
a
t
t
f
c
n
“
o
r
s
s
I
e
f
i
a
p
o
g
t
a
f
a
[
v
I
s
i
e
s
[
f
g
d
t
T
•924 J.T. Safrit et al. / Vacc
ill be essential, as emphasized in UNAIDS Good Participatory Prac-
ices Guidelines (http://www.unaids.org/sites/default/ﬁles/media
sset/JC1853 GPP Guidelines 2011 en 0.pdf).
. Status
As an outcome of the RV-144 efﬁcacy trial, the Pox-Protein Pub-
ic Private Partnership, consisting of Sanoﬁ, Novartis, NIAID, Bill
 Melinda Gates Foundation, the Military HIV Research Program
MHRP) and the HIV Vaccine Clinical Trials Network, is planning a
ext phase of efﬁcacy trials that may  test the RV144 vaccine reg-
men in a population of men  who have sex with men  in Thailand
nd in heterosexual populations in sub-Saharan Africa [24]. These
rials may  add additional booster immunizations and more potent
djuvants aimed at extending the durability of protection. If vac-
ine efﬁcacy of >50% is demonstrated, a licensure application in
outh Africa is possible as early as 2021. In addition, test of con-
ept efﬁcacy trials are now under consideration for prime-boost
egimens utilizing next generation pox vectors (NYVAC; Sanoﬁ),
p120 boosters (Novartis), and DNA (IPPOX Foundation, VICAL) in
daptive clinical trials.
Parallel efforts are developing vaccine candidates addressing the
yper-variability of HIV, aimed at increasing breadth of antibody
nd T cell responses or focusing responses to conserved regions of
he virus. For example, vaccines based on two different hypotheses
o elicit broad cellular immune responses are in development. One
ocuses immune responses to those regions of HIV that are highly
onserved and therefore may  be required for viral replicative ﬁt-
ess (Oxford University, IAVI, EDCTP) [25], while the other, termed
mosaic antigens” use in silico methods (Los Alamos National Lab-
ratories) to design immunogens that represent diverse sequences
epresenting the optimal choice of epitopes from all known HIV
trains, for broad coverage of circulating viruses (Johnson and John-
on/Janssen, Beth Israel Deaconess Medical Center, NIAID, Ragon
nstitute) [26].
Recent technological advances in B cell immunology, next gen-
ration sequencing, bioinformatics and structural biology have
acilitated the generation of many potent bNAbs. Studies have
dentiﬁed bNAb binding sites on HIV Env, solved structural char-
cterization of Env trimer and Env epitopes with atomic-level
recision, and provided a better understanding of the ontogeny
f bNAbs in HIV infected individuals [27]. Designing immuno-
ens to elicit these bNAbs remains a major challenge, however,
hough structural design is now beginning to yield more stable
nd potent immunogens [28]. bNAbs are also being evaluated
or passive prophylaxis and treatment, in phase I-II clinical tri-
ls (NIH Vaccine Research Center, Rockefeller University, MHRP)
29], and for delivery by gene transfer using adeno-associated
irus vectors (Children’s Hospital of Philadelphia, IAVI) in a phase
 trial [30]. Finally, since the RV-144 trial showed that HIV acqui-
ition could be prevented without bNAbs or robust CD8+ cellular
mmune responses, studies are ongoing to develop vaccines that
licit antibodies that work through other effector mechanisms,
uch as Fc-mediated interactions with the innate immune system
31].
Since the HIV vaccine ﬁeld likely will not see data emerging
rom the next set of efﬁcacy trials until 2019–2020, current strate-
ies are focused on advancing leading candidates through clinical
evelopment, improving vaccine delivery methods and optimizing
he next generation of candidates entering clinical development.
hese include:
HIV Env Trimers: Recent resolution of the structure of a stabilized
HIV Env trimer will lead to clinical evaluation of immunogens
more closely mimicking the native Env glycoprotein. (2016) 2921–2925
• HIV Antibody Epitope Based Vaccines: Recent elucidation of at
least ﬁve major epitopes on HIV Env that bind bNAbs will lead
to the generation of clinical candidates targeting each of these
epitopes, including glycopeptides (see also below), computation-
ally derived scaffolds and novel immunogens designed to bind to
putative germline ancestors of the bNAbs.
• Sequential Immunization with Different Immunogens: Increased
understanding of how bNAbs evolve along with virus evolution in
the human host will lead to testing the hypothesis that sequential
immunization with different immunogens may  be required to
drive antibody afﬁnity maturation.
• Conserved/Mosaic Hybrids: Next generation immunogens to
elicit broad cellular immune responses will take advantage
of the attributes of both conserved and mosaic antigens to
drive breadth, depth and enhanced coverage of cellular immune
responses by immunization.
• Replication Competent Viral Vectors: Replicating adenovirus,
poxvirus, vesiculostomatitis virus and Sendai virus vectors are in
preclinical and early clinical development. Research in this area
will focus on vectors generating persistent infection, mucosal
delivery, and targeting of the gut-associated lymphoid tissues all
in hope of mimicking the efﬁcacy of a live attenuated vaccine.
• Antigen Presentation Systems and Novel Adjuvants: Several
virus-like particle and nanoparticle antigen presentation sys-
tems and novel adjuvants are in development. They are based
on advances in understanding of innate and adaptive immune
linkages.
• Synthetic Biology Technologies: Novel DNA and RNA vaccines are
being explored in efforts to achieve the efﬁcacy of viral vectors
while mitigating concerns of anti-vector immunity. Delivery of
such genetic vaccines by electroporation has shown promise in
clinical trials.
• Glycobiology: Advances in glycobiology are yielding important
insights for HIV vaccine research, both in characterization and
synthesis of targets recognized by bNAbs, and in strategies
to manipulate vaccine-induced Fc-mediated immune responses
such as ADCVI and ADCC.
6. Financing the development of an HIV vaccine
HIV vaccine R&D is funded by the public and private sector
[32]. In 2014, 841 million USD was available, invested in basic
research (29%), preclinical research (33%), clinical research (34%),
and other (4%). Funding over the last several years has ﬂat-lined,
and is increasingly vulnerable due to its dependency on just two
major sources: 84% of funding comes from the US government and
the Bill and Melinda Gates Foundation. Over the next 5–10 years,
it will be essential for funding to respond to the global pipeline,
notably the planned efﬁcacy studies and efforts to leverage new
knowledge, such as in the bNAb domain, to design and evaluate
novel vaccine approaches.
For HIV vaccines that ultimately reach the state of licensure, ini-
tiatives such as The Vaccine Alliance GAVI can help to ensure broad
roll-out and access in countries and populations most affected by
HIV/AIDS. HIV vaccines, notably those with a high level of efﬁcacy
and broad coverage (across HIV variants) will likely be very cost-
efﬁcient, especially when considered against the cost of life-long
antiretroviral treatment. Modeling studies indicate that a preven-
tive HIV vaccine could dramatically reduce the number of new
infections even if coverage is less than 50% in low- and middle-
income countries [33]. A preventive vaccine could be especially
beneﬁcial for people who are unable to access or consistency use
current methods for preventing HIV infection, due to barriers or
dependency on compliance or behavioral change. The best hope
for ending the AIDS pandemic is to develop an effective, accessible
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accine that is delivered in the context of a comprehensive preven-
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